



**In-Common Laboratories**

Head Office: 57 Gervais Drive  
North York, Ontario M3C 1Z2  
(416) 422-3000  
Toll Free: (888) 285-7817  
www.ICLabs.ca

ICL-QC  
57 Gervais Drive  
North York, ON M3C 1Z2  
Canada  
Fax:(416) 385-1957

Patient Name  
**TEST, ALZHEIMER**

Order ID  
**123285**

Health Number

ICL Login Date (mm/dd/yyyy)  
**10/12/2023 10:09AM EDT**

Authorized Requester  
**ICL, ICL**

Date of Birth (mm/dd/yyyy)  
**01/25/1950**

Client's File No.

Report Printed  
**10/27/2023 10:37AM EDT**

**Alzheimer's Disease Biomarkers Panel, CSF**

Sample ID: LON231012001

Final - Received 10/23/2023 2:04PM EDT

Collection Date/Time (mm/dd/yyyy)  
10/12/2023 10:15AM EDT

Order Choice CSF  
Comments:

TEST	RESULT	FLAG	NORMAL/THERAPEUTIC RANGE	UNITS	TEST SITE
General Alzheimer's Comment,CSF	See Comment				LON
*Compared to CSF concentrations of ABeta42, pTau, and Tau individually, the pTau/ABeta42 ratio has been shown to better correlate with Alzheimer's disease-related pathologic change as measured by amyloid PET scan.					
*Please note that improper specimen collection or handling technique may falsely decrease ABeta42 and increase the pTau/ABeta42 ratio.					
*Discrepancies in interpretation of the pTau/ABeta42 ratio compared to CSF concentrations of ABeta42, pTau, and/or Tau individually may relate to improper specimen collection/handling, inter-individual variation in beta-amyloid CSF concentration, a disorder related to CSF dynamics, and/or elevation in pTau due to a non-Alzheimer's disease-related pathologic change.					
*Clinical correlation is required. For patients with values near cutoffs, interpretation in the context of clinical history is particularly important.					
BetaAmyloid42 (ABeta42),CSF	<b>500.0</b>	<b>L</b>	>=1030.1	pg/mL	LON
Phosphorylated Tau 181 (pTau),CSF	<b>28.00</b>	<b>H</b>	<=27.00	pg/mL	LON
Total Tau (Tau),CSF	<b>305</b>	<b>H</b>	<=300	pg/mL	LON
Alzheimer Interp (ABeta42,pTau,Tau),CSF	See Below				LON

Abnormal CSF concentrations of ABeta42, pTau, and Tau. These results are consistent with Alzheimer's disease-related pathologic change, but are not diagnostic of Alzheimer's disease on their own. Clinical correlation is required.

Patient Complete Name: TEST, ALZHEIMER

Order ID: 123285

Current Page Number: 1

Total Pages Count: 2



**In-Common Laboratories**

Head Office: 57 Gervais Drive  
North York, Ontario M3C 1Z2  
(416) 422-3000  
Toll Free: (888) 285-7817  
www.ICLabs.ca

ICL-QC  
57 Gervais Drive  
North York, ON M3C 1Z2  
Canada  
Fax: (416) 385-1957

Patient Name  
**TEST, ALZHEIMER**

Sex  
**F**

Date of Birth (mm/dd/yyyy)  
**01/25/1950**

Order ID  
**123285**

Client's File No.

Health Number

ICL Login Date (mm/dd/yyyy)  
**10/12/2023 10:09AM EDT**

Report Printed  
**10/27/2023 10:37AM EDT**

Authorized Requester  
**ICL, ICL**

**Alzheimer's Disease Biomarkers Panel, CSF**

Sample ID: LON231012001

Final - Received 10/23/2023 2:04PM EDT

Collection Date/Time (mm/dd/yyyy)  
10/12/2023 10:15AM EDT

Order Choice CSF  
Comments:

TEST	RESULT	FLAG	NORMAL/THERAPEUTIC RANGE	UNITS	TEST SITE
pTau:ABeta42 Ratio,CSF	<b>0.0560</b>	<b>H</b>	<=0.0230		LON
Alzheimer Interp (pTau:ABeta42Ratio), CSF	See Below				LON

Abnormal pTau/ABeta42 ratio. This is consistent with Alzheimer's disease-related pathologic change, but is not diagnostic of Alzheimer's disease on its own. Clinical correlation is required.

**Reporting Laboratories:**

(1) LON-London, London Health Sciences Centre, 339 Windermere Road, London, ON N6A 5A5,

Patient Complete Name: TEST, ALZHEIMER

Order ID: 123285

Current Page Number: 2

Total Pages Count: 2